Iovance Biotherapeautics (IOVA.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Event Tracking

Nov20

Mizuho and TD Cowen Maintain Buy Ratings for Iovance Biotherapeutics

20:22

Nov6

H.C. Wainwright and Barclays Analysts Reiterate Buy Rating on Iovance Biotherapeutics

16:23

Iovance Biotherapeutics released FY2025 9 Months Earnings on November 6 Pre-Market (EST), actual revenue USD 176.73 M, actual EPS USD -0.9442

14:30

Iovance Biotherapeutics released FY2025 Q3 earnings on November 6 Pre-Market EST, actual revenue USD 67.46 M (forecast USD 72.81 M), actual EPS USD -0.2506 (forecast USD -0.2642)

14:30

Nov4

Goonewardene rates Iovance Biotherapeutics as Strong Buy

14:24

Oct30

Iovance Biotherapeutics to Release FY2025 Q3 Earnings on November 6, Pre-Market EST; Forecast Revenue USD 74.48M, EPS USD -0.2642

00:42

Schedules & Filings

Schedules

Filings

Nov6

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 67.46 M, Net Income -91.25 M, EPS -0.2506

Aug7

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 59.95 M, Net Income -111.66 M, EPS -0.3337

May8

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 49.32 M, Net Income -116.16 M, EPS -0.3597

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change